Opinion Review
Copyright ©The Author(s) 2019.
World J Gastroenterol. Jul 21, 2019; 25(27): 3484-3502
Published online Jul 21, 2019. doi: 10.3748/wjg.v25.i27.3484
Table 4 Studies on the ClinicalTrials.gov registry investigating the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on high risk patients for preventing peritoneal metastases from colorectal origin
ClinicalTrials.gov IDPhaseHigh risk criteriaControl vs Treatment arms
NCT01226394 ProphyloCHIP trialPhase IIIComplete resection of minimal abdominal synchronous metastases or perforated tumorsSurveillance vs second-look laparotomy with HIPEC (intraperitoneal oxaliplatin and intravenous 5-FU) after primary resection
NCT02231086 COLOPEC trialPhase IIIT4, N0-2M0 or perforated colon cancerAdjuvant systemic therapy only vs adjuvant systemic therapy + HIPEC, without resection of target organs
NCT02974556 PROMENADE trialPhase IIIT3-T4 tumorsResection of target organs for peritoneal implants, plus HIPEC with oxaliplatin and concomitant i.v., 5-fluorouracil/leucovorin
NCT02179489Phase IIIT4M0 and complete resection of minimal abdominal synchronous metastases or perforated tumorsSurgery vs surgery and HIPEC with mitomycin C (without preventive excision of target organs)
NCT02965248 APEC trialPhase IIT4NanyM0 and T3-NanyM0 + mucinous or signet ring cells histologyAdjuvant systemic chemotherapy alone (arm A) vs systemic chemo + HIPEC with raltitrexed (arm B) or oxaliplatin (arm C)
NCT02614534 HIPEC T4Phase IIIComplete resection of T4a, bNanyM0Surgery vs prophylactic HIPEC with mitomycin plus target organs excision
NCT03413254 COLOPEC-IIPhase IIIComplete resection of T4a, bN0-2M0Routine follow-up (arm A) vs a second exploratory laparoscopy (arm B) and third exploratory laparoscopy (arm C) if the work-up is negative
NCT02974556Phase IIIComplete resection of T3-4NanyM0Systemic chemotherapy alone vs CRS/HIPEC with oxaliplatin and systemic therapy
NCT02758951Phase II/IIIComplete resection of colorectal tumors with ≤ 50% of signet ring cells.Upfront CRS-HIPEC alone vs pre/post perioperative systemic chemotherapy and CRS-HIPEC
NCT02830139Phase IIComplete resection of T3-4NanyM0CRS + systemic chemotherapy vs CRS + HIPEC with paclitaxel + 5-FU + postoperative chemotherapy